全口服CC-486联合维奈克拉治疗急性髓系白血病的1/1b期研究
这项单中心、开放标签的1/1b期研究评估了全口服CC-486联合维奈克拉在复发/难治及新诊断急性髓系白血病(AML)患者中的安全性和疗效。剂量爬坡阶段确定CC-486推荐剂量为300 mg每日第1-14天,常见不良事件包括恶心、腹泻、疲劳和血细胞减少,未出现剂量限制性毒性。研究各阶段均观察到缓解,6例患者成功桥接至造血干细胞移植。
要点
- CC-486联合维奈克拉全口服方案在复发/难治及新诊断AML中可行,推荐剂量为CC-486 300 mg第1-14天。
- ≥3级中性粒细胞减少发生率为97%,≥3级血小板减少为66%,但未出现剂量限制性毒性。
- 各阶段均观察到缓解,6例患者成功桥接至造血干细胞移植。
核心结论
- 全口服CC-486联合维奈克拉在复发/难治和新诊断AML中显示出可行性,推荐剂量为CC-486 300 mg每日第1-14天。
- 研究各阶段均观察到缓解,6例患者成功桥接至造血干细胞移植。
研究设计与样本
- 单中心、开放标签、1/1b期研究,采用3+3设计进行剂量爬坡。
- 剂量爬坡阶段CC-486设200 mg和300 mg两个队列(第1-14天口服),维奈克拉400 mg/日口服28天(初始按标准进行患者内剂量递增)。
- 扩展阶段纳入10例复发/难治AML和16例新诊断AML患者。
主要发现
- 最常见不良事件包括恶心、腹泻、疲劳和血细胞减少。
- ≥3级中性粒细胞减少发生率为97%,≥3级血小板减少发生率为66%。
- 两个队列均未出现剂量限制性毒性。
- 各阶段均观察到缓解,6例患者成功桥接至造血干细胞移植。
- 测序和代谢组学分析提示该方案对白血病干细胞的影响与传统静脉阿扎胞苷联合维奈克拉相似。
关键数值与推荐
- CC-486推荐剂量为300 mg每日第1-14天口服。
- 维奈克拉400 mg/日口服28天,初始按标准进行患者内剂量递增。
临床怎么用
- 该全口服方案可作为复发/难治及新诊断AML患者的治疗选择,尤其适合需要全口服治疗的患者。
- 治疗期间需密切监测血细胞减少,≥3级中性粒细胞减少和血小板减少发生率较高。
- 部分患者可通过该方案桥接至造血干细胞移植。
局限性
- 单中心、开放标签研究,样本量有限。
- 剂量爬坡阶段仅设两个CC-486剂量队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax with azacitidine is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive induction chemotherapy. CC-486 is the oral formulation of azacitidine that is currently approved for postinduction chemotherapy maintenance in AML. In this single-center, open-label, phase 1/1b study, we investigated CC-486 and venetoclax in patients with relapsed and refractory AML and in those with newly diagnosed disease. In the dose-escalation phase, patients received CC-486 at 1 of 2 cohorts (200 mg by mouth on days 1-14 and 300 mg by mouth on days 1-14). Venetoclax was given at 400 mg/d by mouth for 28 days after an initial intrapatient dose escalation per the standard of care. Using a 3+3 study design for these 2 cohorts, we determined the recommended dose of CC-486 to be 300 mg daily on days 1 to 14. The most common adverse events included nausea, diarrhea, fatigue, and cytopenias. The incidence of grade ≥3 neutropenia or thrombocytopenia was 97% and 66%, respectively. There were no dose-limiting toxicities in either cohort. The expansion phase of the study consisted of 10 additional patients with relapsed and refractory AML and 16 patients with newly diagnosed AML. Responses were seen in all phases of the study, and 6 patients were successfully bridged to hematopoietic stem cell transplant. Correlative analyses including sequencing and metabolomics performed on patient samples suggested that this regimen had a similar effect on leukemia stem cells compared with conventional (IV) azacitidine and venetoclax. This trial was registered at www.clinicaltrials.gov as NCT05287568.
引用
- Amaya ML, Abbott D, McMahon C, et al. A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia. Blood Adv. 2026. PMID: 42498285. doi:10.1182/bloodadvances.2026020179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。